Analysts Forecast Tarsus Pharmaceuticals Q4 Revenue $140M, EPS -$0.11, 39% Upside
Tarsus Pharmaceuticals projects Q4 2025 revenue of $140 million and a loss of $0.11 per share, with full-year 2025 revenue forecast at $440 million and EPS of -$1.49. Analysts’ average one-year price target of $91.38 implies 39% upside and a strong buy consensus (1.40).
1. Q4 2025 Earnings Preview
Tarsus Pharmaceuticals is set to report Q4 2025 results on Feb. 23, with consensus revenue of $140 million and an expected loss of $0.11 per share. Full-year 2025 estimates call for $440 million in revenue and a -$1.49 EPS.
2. Estimate Revisions
Over the past 90 days, full-year 2025 revenue estimates held at $440 million while 2026 revenue forecasts dipped from $680 million to $670 million. EPS estimates improved slightly for 2025 (from -$1.50 to -$1.49) but fell for 2026 (from $1.70 to $1.63).
3. Q3 2025 Reported Results
In Q3 2025, Tarsus generated $120 million in revenue, exceeding expectations by 3.02%, and reported a loss of $0.30 per share, beating the -$0.38 estimate by 20%. The stock declined 4.62% on the day following the release.
4. Analyst Price Targets and Ratings
Eight analysts set a one-year average price target of $91.38 (range $85–$100), implying 39.42% upside from current levels, while a GF Value estimate of $260.54 suggests 297.5% potential. Nine brokerages assign an average recommendation of 1.40, indicating a Buy status.